Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
作者信息
Alexander James L, Selinger Christian P, Powell Nick
机构信息
Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
出版信息
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):987-988. doi: 10.1016/S2468-1253(21)00374-5. Epub 2021 Oct 13.
Abstract
摘要
相似文献
1
Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.炎症性肠病免疫抑制患者的严重急性呼吸综合征冠状病毒2型疫苗第三剂接种
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):987-988. doi: 10.1016/S2468-1253(21)00374-5. Epub 2021 Oct 13.
2
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.炎症性肠病患者接受生物治疗时对SARS-CoV-2疫苗的接种情况。
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):989. doi: 10.1016/S2468-1253(21)00347-2. Epub 2021 Oct 14.
3
Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel Disease.炎症性肠病患者第三次接种疫苗前后对严重急性呼吸综合征冠状病毒2的抗体反应
Dig Dis. 2025;43(1):19-27. doi: 10.1159/000542353. Epub 2024 Nov 30.
4
Managing Immunosuppressed Patients With Inflammatory Bowel Disease During a Measles Outbreak.在麻疹疫情期间管理炎症性肠病的免疫抑制患者
Am J Gastroenterol. 2019 Oct;114(10):1563-1565. doi: 10.14309/ajg.0000000000000396.
5
Very Low Immunization Rate in Kidney Transplant Recipients After One Dose of the BNT162b2 Vaccine: Beware not to Lower the Guard!肾移植受者接种一剂BNT162b2疫苗后免疫率极低：谨防放松警惕！
Transplantation. 2021 Oct 1;105(10):e148-e149. doi: 10.1097/TP.0000000000003818.
6
Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic.寒冬将至！2019冠状病毒病大流行期间炎症性肠病患者疫苗接种的临床、免疫学及实际考量
Gastroenterology. 2021 Feb;160(3):639-644. doi: 10.1053/j.gastro.2020.10.013. Epub 2020 Oct 14.
7
Delaying the second dose of covid-19 vaccines.推迟新冠疫苗的第二剂接种。
BMJ. 2021 Mar 18;372:n710. doi: 10.1136/bmj.n710.
8
Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.土耳其 IBD 组织关于 COVID-19 大流行期间炎症性肠病管理建议的立场声明。
Turk J Gastroenterol. 2021 Jun;32(6):488-492. doi: 10.5152/tjg.2021.280721.
9
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study).SARS-COV-2 疫苗加强针可提高炎症性肠病患者亚最佳血清转化率。GETECCU（VACOVEII 研究）前瞻性多中心研究结果。
Gastroenterol Hepatol. 2024 Oct;47(8):821-833. doi: 10.1016/j.gastrohep.2023.11.004. Epub 2023 Nov 23.
10
Considerations in boosting COVID-19 vaccine immune responses.增强新冠病毒疫苗免疫反应的考量因素。
Lancet. 2021 Oct 9;398(10308):1377-1380. doi: 10.1016/S0140-6736(21)02046-8. Epub 2021 Sep 14.
引用本文的文献
1
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.炎症性肠病患者接种三剂新冠病毒疫苗（VIP）后针对新冠病毒奥密克戎BA.4/5和野生型病毒的中和抗体反应：一项前瞻性、多中心队列研究
EClinicalMedicine. 2023 Oct 5;64:102249. doi: 10.1016/j.eclinm.2023.102249. eCollection 2023 Oct.
2
Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients.抗TNFα治疗对儿童炎症性肠病患者针对BNT162b2 mRNA新冠疫苗的体液免疫反应的影响
Vaccines (Basel). 2022 Sep 27;10(10):1618. doi: 10.3390/vaccines10101618.
3
Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation.评估接种国药/BBIBP-CorV 疫苗的肾移植患者的 SARS-CoV-2 血清水平。
Transplant Proc. 2022 Dec;54(10):2663-2667. doi: 10.1016/j.transproceed.2022.08.012. Epub 2022 Aug 15.
4
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
5
Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.2019冠状病毒病疫苗在炎症性肠病患者中的有效性和安全性
Gastroenterol Hepatol (N Y). 2022 Mar;18(3):145-155.
6
Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis.新型冠状病毒疫苗在炎症性肠病患者中的安全性：系统评价和荟萃分析。
Dig Liver Dis. 2022 Jun;54(6):713-721. doi: 10.1016/j.dld.2022.03.005. Epub 2022 Mar 22.
7
Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.COVID-19 疫苗在 9447 例 IBD 患者中的有效性和持久性：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2022 Jul;20(7):1456-1479.e18. doi: 10.1016/j.cgh.2022.02.030. Epub 2022 Feb 19.
8
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.利妥昔单抗治疗的类风湿关节炎患者对两剂和三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的体液和细胞免疫反应：一项前瞻性队列研究
Lancet Rheumatol. 2022 Mar;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5. Epub 2021 Dec 23.
Zotero 插件